This Special Issue contains case studies about the experiences of women with vulvar and vaginal atrophy during treatment with ospemifene. It covers the effects of ospemifene on bone markers, its use in breast cancer survivors, and in women with dyslipidemia, urinary incontinence or VVA-related sexual dysfunction, and its concomitant use with laser therapy.
Editorial
This editorial article introduces a Special Focus Issue entitled “Treatment of Vulvar and Vaginal Atrophy: Clinical Experience with Ospemifene”. Ospemifene is a selective estrogen receptor modulator indicated for treatment of moderate-to-severe symptomatic vulvar and vaginal atrophy in postmenopausal women who are not candidates for local vaginal estrogen therapy or have contraindications for estrogen products.
Case Report
In this case report, outcomes in relation to bone homeostasis, bone mineral density (BMD), and osteopenia– osteoporosis are examined in postmenopausal women during treatment with ospemifene for vulvar and vaginal atrophy (VVA), a component of the genitourinary syndrome of menopause.
Case Report
Women with breast cancer are at a higher risk of developing vulvar and vaginal atrophy (VVA). Ospemifene is approved to treat VVA in postmenopausal women with a history of breast cancer after completion of all breast cancer (including adjuvant) treatments. This article examines the background characteristics and outcomes in two postmenopausal women with a history of breast cancer who were treated with ospemifene for VVA.
Case Report
This case study reports the experience of a postmenopausal woman with VVA who required escalation from local therapy and presented CVD risk factors (family history and hypertension).
Case Report
The two case studies presented in this article support the findings from a series of retrospective studies, which showed that urinary symptoms improved in women with overactive bladder syndrome who were receiving ospemifene for vulvovaginal atrophy (VVA), a component of genitourinary syndrome of menopause.
Case Report
This article reports the clinical course of two women with dyspareunia preventing sexual intercourse who were treated with ospemifene and laser therapy.
Case Report
The case studies presented in this article follow the progress of two women who began treatment with ospemifene for the main presenting symptom of dyspareunia.
